Actinium Pharmaceuticals Presents New Preclinical Data From Its ATNM-400 Across Non-Small Cell Lung Cancer At 39th Annual Congress Of European Association Of Nuclear Medicine

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) presented new preclinical data on its targeted radiotherapy ATNM-400, showcasing its antitumor potential in non-small cell lung cancer, colorectal cancer, and ovarian cancer models. The findings were shared during an oral presentation and two e-posters at the 39th Annual Congress of the European Association of Nuclear Medicine held from October 17–21, 2026, in Vienna, Austria.